Feasibility Evaluation
Structured feasibility study to validate MeticTouch® compatibility with your compound
- On-site device demonstration
- Collaborative study at agreed CRO
- PK/efficacy readout in 3-6 months
- Data ownership negotiable
Partnership &
Licensing
We partner with pharmaceutical companies to advance their therapeutic assets using the MeticTouch® non-invasive delivery platform. We are structured as an asset-light, technology-enabling company.
How We Work Together
Technology Licensing
License the MeticTouch® platform for use with your in-market or proprietary therapeutic assets.
- Turnkey drug delivery platform
- Access for defined scope
- Trial and registration support
- Product supply chain in place
Co-Development
Joint development of MeticTouch® for a specific therapeutic asset, with shared IP and co-commercialisation rights.
- Shared R&D investment
- Joint IP ownership
- Co-commercialisation rights
- Preferred for novel therapy assets
Information Request
Complete the form below to initiate a request.
Frequently Asked
Questions
Yes. We have extensive experience providing feasibility evaluations in various formats, including on-site demonstrations at our facilities and collaborative studies conducted at a mutually agreed CRO. This is our preferred starting point for new partnerships.
We are happy to share a summary of our preclinical data package — covering efficacy, PK, and safety findings — prior to CDA execution. Detailed study protocols, full reports, and raw experimental data are available under a signed NDA.
We have validated compatibility with a wide range of small molecules, TKIs, peptides, antibodies (full antibody and fragments), and gene therapeutics. Including Dexamethasone, Triamcinolone, Bevacizumab, Aflibercept, Ranibizumab (10mg/ml & 100mg/ml), Faricimab etc. MeticTouch® is also directly compatible with various formulations including suspension, injectables, high-concentration high-viscosity formulations.
MeticTouch® is trial-ready: preclinical evaluation is complete, ISO 13485 quality management systems are in place, and clinical-grade units have been manufactured. We are targeting First-in-Human trial initiation in 2027.
The non-invasive transscleral pathway is a compelling alternative for large-molecule gene therapy delivery. Having demonstrated successful delivery and transfection in vivo, we are actively seeking partners to explore this application. Please contact us to discuss.
Get In Touch
Tell us about your molecule, indication, and partnership interest. Our business development team will follow up with next steps for data-pack access or a feasibility discussion.
We also welcome inquiries on the details and status of MeticTouch® from patients and healthcare professionals.
You can also contact us directly at bd@opharmic.com.